Floatz logo

Melphalan

Hematopoietic And Lymphoid System Neoplasm

Explore 134 assets in Hematopoietic And Lymphoid System Neoplasm →
Floatz Rating
BB66/100
Confidence
Indicative
v0.2
Sponsor
Thomas Jefferson University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05088356CT.gov
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
—Active Not Recruiting———
NCT03159702CT.gov
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
—Completed———
NCT02988466CT.gov
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
—Completed———
NCT01350258CT.gov
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
—Terminated———
NCT01010217CT.gov
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
—Completed———
NCT00997386CT.gov
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Hematopoietic And Lymphoid System Neoplasm

AssetSponsorPhaseRating
Melphalan (this asset)Thomas Jefferson UniversityP2BB · 66
AdriamycinOHSU Knight Cancer InstituteP4BBB
TeclistamabJanssen Pharmaceutical K.K.P2BB
DexasoneCity of Hope Medical CenterP3BB
CyclophosphamideNational Cancer Institute (NCI)P3BB
Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf)Gamida Cell ltdP3BB
BortezomibOHSU Knight Cancer InstituteP4BB
EtoposideCiusss de L'Est de l'Île de MontréalP2BB
PembrolizumabVividion Therapeutics, Inc.P3BB

+42 more in the Hematopoietic And Lymphoid System Neoplasm cohort

Other indications for Melphalan

IndicationSponsorPhaseRating
Diffuse Large B-Cell Lymphoma—P4BBB · 76
Myelodysplastic/Myeloproliferative Neoplasm—P2/3BBB · 76
Cancer Of Unknown Primary Site—P2/3BBB · 72

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Melphalan in Hematopoietic And Lymphoid System Neoplasm. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/melphalan-hematopoietic-and-lymphoid-system-neoplasm

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →